Molecular aspects of hepatic encephalopathy;Aspectos moleculares de la encefalopatía hepática

Neurologia

Volumn 25, Issue 4, 2010, Pages 239-247

  Marquez Aguirre A L ^a   Canales Aguirre, A A ^a   Gomez Pinedo U ^b   Galvez Gastelum F J ^c  

^a CENTRO DE INVESTIGACIÓN Y ASISTENCIA EN TECNOLOGÍA Y DISEÑO DEL ESTADO DE JALISCO   (Mexico)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Ammonia; Hepatic encephalopathy; Manganese; Neurotoxins; Oxidative stress

Indexed keywords

4 AMINOBUTYRIC ACID; DOPAMINE; GLUTAMIC ACID; NEUROTOXIN;

ASTROCYTE; HEPATIC ENCEPHALOPATHY; HUMAN; METABOLISM; NERVE CELL; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

ASTROCYTES; DOPAMINE; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; HEPATIC ENCEPHALOPATHY; HUMANS; NEURONS; NEUROTOXINS; OXIDATIVE STRESS;

EID: 77956643845     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2009.12.001     Document Type: Short Survey

References (51)

1. Social Security Online. Disponible en: http://www.ssa.gov.
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-18.
3. Rodriguez-Hernandez H, Jacobo-Karam JS, Castañón-Santillán Mdel C, et al. [Survival in patients with liver cirrhosis at the Durango, IMSS Regional General Hospital]. Gac Med Mex. 2002;138:325-30.
4. Butterworth RF. Hepatic encephalopathy-a serious complication of alcoholic liver disease. Alcohol Res Health. 2003;27:143-5.
5. Montes S, Alcaraz-Zubeldia M, Muriel P, Ríos C. Striatal manganese accumulation induces changes in dopamine metabolism in the cirrhotic rat. Brain Res. 2001;891:123-9.
6. Salgado S, Garcia J, Vera J, et al. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol Ther. 2000;2:545-51.
7. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci (Lond). 2007;112:265-80.
8. Lotersztajn S, Julien B, Teixeira-Clerc F, Grenard P, Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol. 2005;45:605-28.
9. Garcia-Moreno LM, Conejo NM, González-Pardo H, et al. Evaluation of two experimental models of hepatic encephalopathy in rats. Braz J Med Biol Res. 2005;38:127-32.
10. Siller-López F, Sandoval A, Salgado S, et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology. 2004;126:1122-33.
11. Jalan R, Shawcross D, Davies N. The molecular pathogenesis of hepatic encephalopathy. IJBCB. 2003;1471:1-7.
12. Méndez M, Méndez-López M, López L, et al. Spatial memory alterations in three models of hepatic encephalopathy. Behav Brain Res. 2008;188:32-40.
13. Córdoba J, Mínguez B. Hepatic encephalopathy. Sem Liver Dis. 2008;28:70-80.
14. Groeneweg M, Moerland W, Quero JC, et al. Screening of subclinical hepatic encephalopathy. J Hepatol. 2000;32:748-53.
15. Clasificación de Child-Pugh. Disponible en: http://www.hepatitis.cl/child-pugh.htm.
16. Haussinger D, Schliess F, Kircheis G. Pathogenesis of hepatic encephalopathy. J Gastroenterol Hepatol. 2002;17:S256-9.
17. Brusilow S. Hyperammonemic encephalopathy. Medicine. 2002;81:240-9.
18. Chun-Jung C, Su-Lan L. Oxidative stress involves in astrocytes alterations induced by manganese. Exp Neurol. 2002;175:216-25.
19. Hazell A. Astrocytes and manganese neurotoxicity. Neurochem Int. 2002;41:271-7.
20. Su-Jin Y, Kim M, Kim S, et al. Induction of TGF-β-inducible geneh3 (βig-h3) by TGF-β1 in astrocytes: implications for astrocyte response to brain injury. Mol Brain Res. 2002;107:57-64.
21. Butterworth RF. Neuronal cell death in hepatic encephalopathy. Metab Brain Dis. 2007;22:309-20.
22. Ong J, Mullen D. Hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2001;13:3325-34.
23. Shawcross D, Jalan R. Dispelling myths in the treatment of hepatic encephalopathy. Lancet. 2005;365:431-3.
24. Sassine MP, Mergler D, Bowler R, Hudnell HK. Manganese accentuates adverse mental health effects associated with alcohol use disorders. Biol Psychiatry. 2002;51:909-21.
25. Hazell A, Butterworth R. Hepatic encephalopathy: an updateof pathophysiologic mechanism. Proc Soc Exp Biol Med. 1999;222:99-112.
26. Ramesh G, Ghosh D, Gunasekar P. Activation of early signaling transcription factor, NF-kB following low level manganese exposure. Toxicol Lett. 2002;136:151-8.
27. Erikson K, Dobson AW, Dorman DC, Aschner M. Manganese exposure and induced oxidative stress in the rat brain. Sci Tot Env. 2004;334:409-16.
28. Kosenko E, Venediktova N, Kaminsky Y, et al. Sources of oxygen radicals in brain in acute ammonia intoxication in vivo. Brain Res. 2003;981:193-200.
29. Hilgier W, Anderzhanova E, Oja SS, et al. Taurine reduces ammonia- and N-methyl-D-aspartate-induced accumulation of cyclic GMP and hydroxyl radicals in microdialysates of the rat striatum. Eur J Pharmacol. 2003;468:21-5.
30. Kosenko E, Kaminski Y, Lopata O, et al. Blocking NMDA receptors prevents the oxidative stress induced by acute ammonia intoxication. Free Radic Biol Med. 1999;26:1369-74.
31. Kosenko E, Kaminsky Y, Kaminsky A, et al. Superoxide production and antioxidant enzymes in ammonia intoxication in rats. Free Radic Res. 1997;27:637-44.
32. Warskulat U, Görg B, Bidmon HJ, et al. Ammonia-induced heme oxygenase-1 expression in cultured rat astrocytes and rat brain in vivo. Glia. 2002;40:324-36.
33. Song G, Dhodda VK, Blei AT, et al. GeneChip analysis shows altered mRNA expression of transcripts of neurotransmitter and signal transduction pathways in the cerebral cortex of portacaval shunted rats. J Neurosci Res. 2002;68: 730-7.
34. Ryter SW, Choi AM. Heme oxygenase-1: molecular mechanisms of gene expression in oxygen-related stress. Antioxid Redox Signal. 2002;4:625-32.
35. Negru T, Ghiea V, Pasarica D. Oxidative injury and other metabolic disorders in hepatic encephalopathy. Rom J Physiol. 1999;36:29-36.
36. Norenberg MD, Jayakumar AR, Rama Rao KV. Oxidative stress in the pathogenesis of hepatic encephalopathy. Metab Brain Dis. 2004;19:313-29.
37. Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr. 2000;130: S1007-15.
38. Mark LP, Prost RW, Ulmer JL, et al. Pictorial review of glutamate excitotoxicity: fundamental concepts for neuroimaging. Am J Neuroradiol. 2001;22:1813-24.
39. Ahboucha S, Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at GABA from the molecular standpoint. Metab Brain Dis. 2004;19:331-43.
40. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328:1046.
41. Giges B, Dein HL, Sborov VM, et al. Experimental hepatic coma. Surg Gynecol Obstet. 1953;97:763-8.
42. Yamamoto HA. Brain phenylalanine and tyrosine levels and hepatic encephalopathy induced by CCl 4 in rats. Toxicology. 1990;61:241-7.
43. Matsushita M, Yamamoto T, Gemba H. The role of astrocytes in the development of hepatic encephalopathy. Neurosci Res. 1999;34:271-80.
44. Hilgier W, Olson JE. Brain ion and amino acid contents during edema development in hepatic encephalopathy. J Neurochem. 1994;62:197-204.
45. Montes S, Alcaraz-Zubeldia M, Muriel P, Rios C. Role of manganese accumulation in increased brain glutamine of the cirrhotic rat. Neurochem Res. 2003;28:911-7.
46. Blitzer BL, Waggoner JG, Jones EA, et al. A model of fulminant hepatic failure in the rabbit. Gastroenterology. 1978;74:664-71.
47. Lindros KO, Jarvelainen HA. Chronic systemic endotoxin exposure: an animal model in experimental hepatic encephalopathy. Metab Brain Dis. 2005;20:393-8.
48. Antoni M. Hepatic encephalopathy: from pathophysiology to treatment. Digestion. 2006;73:86-93.
49. De Melo RT, Charneski L, Hilas O. Rifaximib for the treatmentof hepatic encephalopathy. Am J Health Syst Pharm. 2008;65:818-22.
50. Shores NJ, Keeffe EB. Is oral L-acyl-carnitine an effective therapy for hepatic encephalpathy? Review of the literature. Dig Dis Sci. 2008;53:2330-3.
51. Camacho-Muñoz B, Hernández-Ramos FJ, Ortega-Martínez de Victoria L. Enfermedad de Creutzfeldt-Jakob y encefalopatía hepática: coexistencia en la misma paciente. Rev Neurol. 2001;33:540-4.